2022

1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

   European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331